News and Trends 16 Nov 2017 German Diagnostics Firm Tackles Early Detection of Cancer, Alzheimer’s and Parkinson’s Hummingbird Diagnostics has teamed up with Saarland University to develop molecular diagnostics that can detect serious diseases early using blood samples. Based in Heidelberg, Germany, Hummingbird Diagnostics develops early diagnostics in multiple disease areas, ranging from cancer to cardiovascular and neurodegenerative disease. Its technology is based in the detection of miRNA, molecules that are involved […] November 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Nov 2017 Spanish Biotech Gets €2.4M to Spot Myocardial Infarction Before it’s Too Late GlyCardial Diagnostics believes it has the technology to prevent premature myocardial infarctions, 80% of which are preventable. Barcelona-based GlyCardial Diagnostics is a biotech, which spun-out from the Catalan Institute of Cardiovascular Science. The startup focuses on the development of an in vitro diagnostic device for myocardial ischemia, which is based on the detection of Apo J-Glyc in the […] November 13, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2017 Roche Partners with French Startup to Diagnose Septic Shock In its first partnership with a biotech startup, Roche Diagnostics will help develop a blood test to accompany Inotrem’s experimental therapy for septic shock. Roche Diagnostics has announced a research collaboration with Inotrem, a biotech startup based in Nancy, France. The deal, for which the amount was undisclosed, concerns the development of a companion diagnostic test […] November 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2017 Personalized Breast Cancer Treatment Coming Soon with Help from Spanish Biotech Inbiomotion has published the results of a Phase III study looking at its MAFTest to personalized approaches to the disease. Inbiomotion, based in Barcelona’s biotech hub, works on a highly selective biomarker for breast cancer. A Phase III study demonstrated that breast cancer patients that would benefit from zoledronic acid therapy can be selected, helping clinicians offer […] October 19, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2017 Biotech Crosses the Channel to Raise €9.7M for its Diagnostics Tools Novacyt will use the money raised on the AIM market, London, to expand its manufacturing capacity and continue research looking into new techniques. Novacyt specializes in diagnostic tools for a number of indications, including cancer and infectious diseases. Today, it has announced that it has raised €9.7M by placing stocks on the London-based Alternative Investment Market (AIM). […] October 18, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2017 Market Ready HIV Self-Test Gets the Thumbs Up from the European Union Technology allowing individuals to accurately test themselves for HIV has received a CE Mark from the EU, meaning it can soon be released onto the market. The EU has awarded a CE Mark to an HIV self-test, developed by world-leading diagnostics developer, Atomo Diagnostics, Sydney, Australia. The world’s first at-home device detects the presence of Human Immunodeficiency Virus […] October 10, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2017 Series D Boost will Bring Artificial Intelligence to Diagnostics Worldwide Sophia Genetics has raised $30M (€25M) in Series D that will be directed to growing and improving its artificial intelligence platform for genetic diagnostics. The Swiss company Sophia Genetics has announced today a new round of funding, led by Balderton Capital, and joined by 360º Capital Partners and existing investors Invoke Capital and Alychlo. The […] September 13, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2017 Finnish AI Biotech Raises €14M to Open the Bottleneck of Next-Generation Sequencing Blueprint Genetics has raised €14M to boost its genetic diagnostics platform, using artificial intelligence to interpret next-generation sequencing data. Based in Helsinki, Finland, Blueprint Genetics is a startup that addresses the main bottleneck of genetic testing through next-generation sequencing (NGS), the interpretation of massive volumes of data, with the aid of artificial intelligence (AI). Its […] July 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2017 Enterome and Nestle Launch a New Microbiome Diagnostics Company Microbiome Diagnostics Partners will develop diagnostics tests with Enterome’s microbiome platform IP and a €20M investment from Nestlé. Nestlé Health Science and Enterome have created Microbiome Diagnostics Partners (MDP) as a joint venture split 50% between both parties. Nestlé has invested €20M for its stake in the new company as well as the exclusive option to commercialize […] July 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jul 2017 British Liquid Biopsy for Ovarian Cancer Outperforms the Gold Standard The British company Angle has announced results from a large-scale trial that seem to indicate its liquid biopsy technology could surpass the gold standard in ovarian cancer diagnosis. Angle, in the UK, is developing liquid biopsy tests to replace biopsies in the diagnosis of cancer. The company has announced results from a 400-patient trial in […] July 4, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jun 2017 German Biotech Raises €25M to Fuel Diagnostics of Rare Diseases Centogene has raised €25M in a Series A round to support the global expansion of its genome analysis platform, which is specialized in rare diseases. The German biotech Centogene is pioneering the development of genetic diagnostic tests to address the challenges of personalized medicine in order to match therapies more effectively to patients. Founded in 2005, the […] June 13, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 24 May 2017 Top Pharma eye British Tech to Predict Response to Checkpoint Inhibitors Oxford BioDynamics will start the development of an epigenetic test to screen patients for a favorable response to anti-PD-L1 drugs. Oxford BioDynamics has announced an agreement with two of the top 10 global pharma to initiate the development of a blood-based test to predict the response to PD-L1 checkpoint inhibitors in patients with non-small cell […] May 24, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email